DDG is focused on screening, tracking, and diagnosing highly infectious diseases that benefit from ultra-low cost and rapid detection for the purpose of early-stage diagnosis. Our platform magneto-optical technology (magnets and lasers) has created portable and reusable devices that can be used to quantitatively diagnose any disease with a known antibody response in one minute with one drop of blood from a fingertip into a plastic disposable cuvette. Our flagship product is the Rapid Assessment of Malaria (RAM), which uses inherent magnetic nanoparticles created by the parasite. Our technology offers a diagnosis at 1/10th the cost of ELISA and 1/100th the limit of detection of Rapid Diagnostic Tests. Through this technology, DDG plans to revolutionize early diagnosis by providing a multiplexed solution. Our partners include Bosch Healthcare, DENKA SEIKEN, Argonne National Lab, and MIT. DDG deployed alpha prototypes into India and Peru last year to gain feedback and then underwent product and user analysis with IDEO. DDG has used those results to develop beta units and will be deploying them into national field trials in India, Nigeria, Malaysia, and Uganda this summer for 3-6 months to obtain individual country approvals and enter the market by Winter 2015. We have generated over letters of interest for over 10 million tests in the malaria market alone.